Dr. Shan Xiong says the technology achieved robust and superior predictive performance across cancer genes of diverse types and across racial backgrounds. Read more
The IASLC’s Supportive Training for Advocates on Research and Science Program Provides Tools, Resources, and Education to Aspiring Patient Research Advocates. Read more
A special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting. Read more
Dr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes. Read more
During WCLC 2024, Dr. Patrick Forde presented data from the CheckMate 77T and CheckMate 816 trials that may help guide lung cancer management in the near future. Read more
Results from the study, presented by Dr. Jin-Ji Yang, suggest that a combination regimen of osimertinib plus savolitinib may be superior to osimertinib alone for EGFR-mutated NSCLC. Read more
A novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC. Read more
Furmonertinib, an oral, brain-penetrant, mutation-selective EGFR TKI, demonstrates activity in patients with EGFR PACC mutations. Read more
The third-generation EGFR TKI joins osimertinib in demonstrating a meaningful progression-free survival benefit for consolidation following chemoradiation. Read more
Experts will focus on overcoming barriers in patient advocacy on a global basis and enhancing the patient-physician partnership. Read more